Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics' Q3 Revenues Rise 41 Percent

NEW YORK (GenomeWeb) – Cellular Dynamics International today reported that its third quarter revenues increased 44 percent year over year.

The Madison, Wis.-based stem cell research products firm reported total revenues of $3.6 million, up from $2.5 million for Q3 2013. Cellular Dynamics fell short of the consensus Wall Street estimate for revenues of $4 million.

Its revenues from collaborations and partnerships more than doubled to $1.9 million from $730,000, and its product sales dropped to $1.7 million from $1.8 million.

The increase in revenues was driven by activity related to contracts with the California Institute for Regenerative Medicine and the Coriell Institute for Medical Research, an increase on a National Heart, Lung, and Blood Institute grant with the Medical College of Wisconsin, and growth in unit volume of iCell Hepatocytes, the firm said in a statement.

During the quarter, the National Eye Institute awarded Cellular Dynamics a $1.2 million contract to develop and manufacture pluripotent stem cells and retinal pigmented epithelial cells for use in a NEI clinical program on dry age-related macular degeneration. The contract is the firm's first deal in the cellular therapeutics market segment, CEO Bob Palay said.

The firm's net loss in the quarter was $8.2 million, or $.52 per share, compared to a net loss of $7.5 million, or $.62 per share, a year ago. Analysts, on average, had expected a loss of $.48 per share.

The firm's R&D spending increased 46 percent to $5.7 million from $3.9 million and its SG&A expenses decreased 4 percent to $5.2 million from $5.4 million.

Cellular Dynamics finished the quarter with $41 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.